Ph2a study planned to be run at approximately 16-18 sites in 4 EU countries (Denmark,
Hungary, Poland and Sweden) enrolling approximately 170 patients to ensure 70 randomized
patients with eosinophilic, moderate to severe asthma. The patients will receive 13 once
weekly inhaled doses of the study drug. Treatment is initiated on top of their ICS/LABA
controller medication, which is then tapered down and withdrawn during a period of 3 weeks
and during the last 3 weeks of treatment the study drug is given as monotherapy. SABA is used
as reliever medication during the whole study period. Primary endpoint is Loss of asthma
control. When the endpoint is met, patients will resume their ICS/LABA, will be followed for
an additional 4 weeks and will thereafter discontinue the study.